The authors discuss sigmoidoscopy screening for colorectal cancer and net cost savings under expert-based assumptions. Costs and savings can also be calculated from the private perspective of a typical U.S. health maintenance organization (HMO), assuming that around 40% of the HMO participants aged 5075 years will no longer be enrolled within 10 years. The authors model also expects favorable health effects from sigmoidoscopy screening, and the decision to screen should be based on a favorable balance between health effects and the costs of screening rather than solely on a cost analysis.
This report is part of the RAND Corporation External publication series. Many RAND studies are published in peer-reviewed scholarly journals, as chapters in commercial books, or as documents published by other organizations.
Our mission to help improve policy and decisionmaking through research and analysis is enabled through our core values of quality and objectivity and our unwavering commitment to the highest level of integrity and ethical behavior. To help ensure our research and analysis are rigorous, objective, and nonpartisan, we subject our research publications to a robust and exacting quality-assurance process; avoid both the appearance and reality of financial and other conflicts of interest through staff training, project screening, and a policy of mandatory disclosure; and pursue transparency in our research engagements through our commitment to the open publication of our research findings and recommendations, disclosure of the source of funding of published research, and policies to ensure intellectual independence. For more information, visit www.rand.org/about/research-integrity.
The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.